Paper Details

  1. Home
  2. Paper Details

[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].

Author: AdamiS, BuffoL, BuoncristianoA, DianiF, GirardelloS, RossiniM, ZamberlanN

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A study of 30 postmenopausal women with osteoporosis compared the effects of alendronate (a bisphosphonate medication) to placebo over six months. Alendronate significantly reduced bone turnover markers within three months and increased lumbar bone mineral density by 3.7% after six months. These positive effects were maintained for six months after stopping treatment. The control group showed a slow decrease in lumbar bone density, which was significant only after 18 months. Femoral bone density was not significantly affected by alendronate, while the control group showed a significant decrease in femoral neck density. This suggests that alendronate may be an effective alternative to estrogen treatment for postmenopausal osteoporosis, particularly in improving lumbar bone density and preventing femoral loss. Larger studies are needed to assess the effectiveness of alendronate in reducing fracture risk.
Paper Details　
Original Abstract of the Article :
The post-menopausal osteoporosis represents an important complication during the climateric period; its clinical, economic and social weight is destined to increase with the aging of the population. The lack of oestrogens is the main etiopathogenetic element; this is the reason why the substitutive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/8927288

データ提供：米国国立医学図書館（NLM）

Alendronate: An Alternative to Estrogen Therapy for Postmenopausal Osteoporosis

This research explores the potential of alendronate, a bisphosphonate drug, as an alternative to estrogen therapy for postmenopausal osteoporosis. The study evaluates the effects of alendronate on bone mineral density (BMD) and bone turnover markers in a group of postmenopausal women. The results suggest that short-term treatment with alendronate can increase lumbar BMD and prevent femoral bone loss. This study highlights the potential benefits of alendronate as a treatment option for postmenopausal osteoporosis.

Alendronate and Bone Health

The study demonstrates that alendronate can effectively reduce bone turnover and increase BMD in postmenopausal women. The findings suggest that alendronate may be a valuable alternative to estrogen therapy for managing postmenopausal osteoporosis. The study emphasizes the importance of continued research to evaluate the long-term effects of alendronate and to determine its potential role in reducing fracture risk. Further research is needed to fully understand the potential benefits and risks of alendronate for postmenopausal osteoporosis, much like a desert explorer must continue their journey to uncover the hidden secrets of a vast and complex landscape.

Managing Postmenopausal Osteoporosis

This research provides valuable information for managing postmenopausal osteoporosis. The study suggests that alendronate may be a viable alternative to estrogen therapy, offering a promising approach for improving bone health. The study encourages continued research to fully understand the long-term effects and potential benefits of alendronate, just as a caravan must carefully plan its route across a vast and unforgiving desert.

Dr.Camel's Conclusion

The researchers, like skilled desert navigators, have uncovered the potential of alendronate as a valuable alternative to estrogen therapy for postmenopausal osteoporosis. Their findings suggest that this bisphosphonate drug can effectively reduce bone turnover and improve bone health. This discovery, like finding a hidden oasis in a vast and arid landscape, offers hope for a better future for those living with postmenopausal osteoporosis. The study underscores the importance of ongoing research and personalized approaches to optimize the use of alendronate, just as a camel must adapt to its environment to thrive in the desert.

Date :
  1. Date Completed 1996-11-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

8927288

DOI: Digital Object Identifier

8927288

SNS
PICO Info
in preparation
Languages

Italian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.